Register for this Live Webinar to Learn More
Glycosite-specific conjugation has emerged as a gold standard for developing next-generation Antibody-Drug Conjugates (ADCs) and other XDCs. However, most existing approaches are hindered by complexity, multi-step reactions, and limited substrate scope.
During this webinar, experts will explore how to enable efficient, scalable, and cost-effective generation of ADCs. You will learn how the novel engineered EndoS2 enzyme, combined with a proprietary disaccharide substrate, drastically simplifies the conjugation process, enabling the efficient, single-step creation of highly potent and stable ADCs.
Whether you are advancing oncology programs, autoimmune therapies, or novel biologics, this session will show how single-step conjugation can accelerate timelines, reduce costs, and enable differentiated product development.
What You’ll Learn
- Current Limitations: limitations of traditional glycosite-specific conjugation methods.
- Advantages of Single-Step Conjugation: How it reduces process complexity, saving time and resources.
- High Efficiency & Versatility: Robust conjugation on native antibodies or Fc-fusion proteins.
- Enhanced ADC Quality: Generation of highly potent, stable XDCs for therapeutic success.
- Commercial Scalability: Proven robustness from lab to commercial manufacturing ready for your clinical and commercial manufacturing needs.
- Broader Applications: Expanding substrate diversification across oncology, Fc-fusion protein therapeutics, autoimmune, and beyond.
Offered Free by: BioDlink
See All Resources from: BioDlink
